**Article**

High Compliance to Mediterranean Diet Associates with Lower Platelet Activation and Liver Collagen Deposition in Patients with Nonalcoholic Fatty Liver Disease

Francesco Baratta 1,*,†, Vittoria Cammisotto 1,†, Giulia Tozzi 2, Mattia Coronati 1,*, Simona Bartimoccia 3, Valentina Castellani 4, Cristina Nocella 1, Alessandra D’Amico 5, Francesco Angelico 6, Roberto Carnevale 3,7,*, Pasquale Pignatelli 1,7, and Maria Del Ben 1,10

---

1 Department of Clinical Internal, Anaesthesiological and Cardiovascular Sciences, Sapienza University of Rome, 00161 Rome, Italy; vittoria.cammisotto@uniroma1.it (V.C.); mattia.coronati@gmail.com (M.C.); cristina.nocella@uniroma1.it (C.N.); pasquale.pignatelli@uniroma1.it (P.P.); maria.delben@uniroma1.it (M.D.B.)

2 Division of Metabolism and Research Unit of Metabolic Biochemistry, Department of Pediatrics, IRCCS Bambino Gesù Children’s Hospital, 00146 Rome, Italy; giulia.tozzi@opbg.net

3 Department of Medical-Surgical Sciences and Biotechnologies, Sapienza University of Rome, 04100 Latina, Italy; simona.bartimoccia@uniroma1.it (S.B.); roberto.carnevale@uniroma1.it (R.C.)

4 Department of General Surgery and Surgical Speciality “Paride Stefanini”, Sapienza University of Rome, 00161 Rome, Italy; valentina.castellani@uniroma1.it

5 Department of Movement, Human and Health Sciences, University of Rome “Foro Italico”, 00135 Rome, Italy; a.damico@studenti.uniroma1.it

6 Department of Public Health and Infectious Diseases, Sapienza University of Rome, 00161 Rome, Italy; francesco.angelico@uniroma1.it

7 Mediterranea Cardiocentro, 80122 Napoli, Italy

* Correspondence: francesco.baratta@uniroma1.it
† These authors contributed equally to this work.

---

**Abstract:** The Mediterranean diet (Med-Diet) is considered the most effective dietary patterns to obtain weight loss in NAFLD patients. Previous evidence suggested that Med-Diet adherence could reduce cardiovascular risk and have a beneficial effect on NAFLD severity. Aim of the study was to investigate the relationship between Med-Diet adherence, platelet activation (PA), and liver collagen deposition. The study was performed in 635 consecutive NAFLD outpatients from the PLINIO study, a prospective observational cohort study aimed to identify non-conventional predictors of liver fibrosis progression in NAFLD. PA was measured by the serum thromboxane B2 (TxB2), and liver collagen deposition by N-terminal propeptide of type III collagen (Pro-C3). Adherence to the Med-diet was investigated by a short nine-item validated dietary questionnaire. Patients with high Med-Diet adherence were older and had less metabolic syndrome and lower serum triglycerides, GGT, TxB2, and Pro-C3. At multivariate regression analyses, in the linear model, the Med-Diet score negatively correlated with both TxB2 (Beta = −0.106; p = 0.009) and Pro-C3 (Beta = −0.121; p = 0.002) and in the logistic model high adherence inversely correlated with higher TxB2 tertiles (II tertile: OR = 0.576, p = 0.044; III tertile: OR = 0.556, p = 0.026) and Pro-C3 tertile (III tertile: OR = 0.488, p = 0.013). Low consumption of red meat inversely correlated with higher TxB2 tertile (II tertile: OR = 0.448, p < 0.001, III tertile: OR = 0.567, p = 0.004). In conclusion, NAFLD patients with high adherence to the Med-Diet show lower PA and liver collagen deposition, suggesting a protective role of the Med-Diet against NAFLD progression and cardiovascular risk. In addition, the correlation between TxB2 and Pro-C3 suggests a link between NAFLD severity and cardiovascular risk.

**Keywords:** nonalcoholic fatty liver disease; Mediterranean diet; platelet activity; liver fibrosis; cardiovascular risk; thromboxane; Pro-C3
1. Introduction

The Mediterranean Diet (Med-Diet) is one of the most studied diets. It is considered a lifestyle approach promoting social exchange, intercultural dialogue, and the respect of diversity [1], favoring environmentally responsible dietary approaches [2] that reduce CO$_2$ consumption [3].

The Med-Diet is an eating pattern characterized by plant-based and minimally processed foods; limited consumption of sweets, red meats, and eggs; moderate wine drinking; and high-quality fats intake [4].

The Med-Diet was firstly described as the dietary pattern of Mediterranean region who suffered less frequently from cardiovascular disease in comparison to other European and American regions with different dietary habits [5]. The protective role of the Med-Diet on cardiovascular disease has been confirmed over time by different studies [6,7].

Researchers investigated the different ways by which the Med-Diet exerts its protective role. The Med-Diet is effective in weight-loss process, producing more favorable effects on glycemic control than other diets [8], reduces insulin resistance (IR) [8], is rich in antioxidant nutrients [9], reduces serum inflammation markers [10], and improves endothelial function [11].

Nonalcoholic fatty liver disease (NAFLD) is a growing disease affecting a quarter of the Western population [12]. NAFLD starts as lipid accumulation in at least 5% of the hepatocytes. Its natural history is characterized by the progressive development of steatohepatitis (NASH) with liver fibrosis build-up, up to the cirrhotic evolution [13]. However, liver disease progression affects only a minority of NAFLD patients, while the majority develops cardio-metabolic disease [14].

While a small proportion of NAFLD patients has a genetic predisposition [15], the increased NAFLD prevalence parallels the obesity epidemic [12]. Not surprisingly, the most effective therapeutic approach to reverse NAFLD is weight loss [16]. Current Guidelines recommend the Med-Diet as the most effective dietary patterns to obtain weight loss in NAFLD patients [16].

The Med-Diet, in NAFLD, reduces liver fat content [17] and associates with lower fibrosis severity [18]. At present, there is no evidence on the association between Med-Diet adherence and N-terminal propeptide of type III collagen (Pro-C3), a cleavage product of liver collagen III deposition during fibrillogenesis [19,20]. Together with type I, type III collagen is highly up-regulated in liver fibrosis [21]. Therefore, Pro-C3 is one of the most reliable circulating markers of liver fibrogenesis [22].

In addition, the Med-Diet improves IR [17,23], associates with lower oxidative stress and bacterial product intestinal translocation [24], and with a better liver enzymatic profile [25]. These effects, together with weight loss, could help reducing cardiovascular risk in patients with NAFLD.

Platelets play a pivotal role in the atherothrombotic process leading to cardiovascular events. While the level of systemic platelet activation, and its impact on cardiovascular risk, has been poorly investigated in NAFLD patients, platelet activity, in the liver context, has been correlated to NAFLD severity in both human and experimental models [26,27]. In humans, the number of platelets identified within liver sinusoids correlates with the NAFLD activity score (NAS) and the presence of ballooning degeneration [26]. In a murine model, platelet adhesion and activation, but not platelet aggregation, were identified as crucial for NASH onset and progression [27]. Regarding the impact of the Med-Diet on platelet activity, several studies proved a negative association between platelet activity and adherence to the Med-Diet [28,29]. However, there is no evidence on the effects of the Med-Diet on platelet function in NAFLD patients.

The evidence above discussed, suggest a possible influence of the Med-Diet on both levels of liver fibrogenesis and platelet activation in NAFLD patients. Therefore, the aim of the present study is to investigate the correlation between Med-Diet adherence, circulating platelet activation markers, and liver collagen deposition.
2. Materials and Methods

This is a post hoc analysis of the PLINIO study (Progression of Liver Damage and Cardiometabolic Disorders in Non-alcoholic Fatty Liver disease: an Observational Cohort study. ClinicalTrials.gov Identifier: NCT04036357) including 655 consecutive NAFLD patients. The Plinio study is a prospective observational cohort study aimed to detect non-conventional factors associated with the progression of liver fibrosis in patients with NAFLD.

We enrolled patients referred to the Day Service of Internal Medicine and Metabolic Disorders of the Policlinico Umberto I University Hospital in Rome with at least one out of the following cardio-metabolic diseases: metabolic syndrome (MetS), overweight/obesity, type 2 diabetes, arterial hypertension, dyslipidemia, or atrial fibrillation (AF). Exclusion criteria were: alcohol abuse (>20 g/day in women and >30 g/day in men) confirmed by the use of Alcohol Use Disorders Identification Test, AUDIT [30]; present or past history of hepatitis B or hepatitis C virus; history of autoimmune hepatitis; presence of other chronic liver diseases; diagnosis of malignancy; use of steatogenic drug (e.g., amiodarone).

Patients presenting inclusion criteria and none of the exclusion criteria underwent liver ultrasound (US). Only patients with evidence of liver steatosis were included in the present analysis.

Anthropometric data (i.e., waist circumference and body mass index, BMI), and clinical and drug history were registered. The presence of cardiovascular and metabolic risk factors was defined according to international guidelines [31–33]. Routine clinical and biochemical evaluations were performed.

Liver US scanning was performed to assess the presence of steatosis. All US were performed by the same operator who was blinded to laboratory values using a GE Vivid S6 apparatus equipped with a convex 3.5 MHz probe; fatty liver was defined according to Hamaguchi score. Hamaguchi score was calculated as follow: echoes intensity arising from liver parenchyma with presence or absence of liver-kidney contrast (0–3 points), clarity of diaphragm visualization (0–2 points), and clarity of liver blood vessel structure (0–1 point). A score of 0 points excluded the presence of steatosis, a score ≥ 1, in presence of increased liver parenchyma echoes, was considered diagnostic for the presence of liver steatosis [34]. Aspartate aminotransferase-to-platelet ratio index (APRI), a non-invasive marker of advanced fibrosis, was calculated as follows

\[
\text{APRI} = \frac{\text{AST (Upper Normal Limit)}}{\text{Platelets count (10^9/l)}} \times 100
\]

Values of APRI > 0.7 were considered positive for predicting significant hepatic fibrosis [35,36].

The study was conducted according to the 2008 update of the Declaration of Helsinki. All patients subscribed informed written consent. Study protocol was approved by the local ethical board of Sapienza-University of Rome (Ref. 2277 prot. 873/11). All co-authors had access to the study data and had reviewed and approved the final manuscript.

2.1. Med-Diet Questionnaire

Adherence to the Med-Diet was investigated by a short 9-item validated and previously described dietary questionnaire. It assigns 1 point for: (1) olive oil (≥1 spoon/day, i.e., tablespoon of 10 gr of olive oil); (2) fruit (≥ 1 serving/day); (3) vegetables or salad (≥1 serving/day); (4) both fruit (≥1 serving/day) and vegetables (≥1 serving/day); (5) legumes (≥2 servings/week); (6) fish (≥3 servings/week); (7) wine (≥1 glass/day, ≤20 g for women and ≤30 g for men; (8) meat (<1 serving/day); (9) both white bread (<1/day) and rice (<1/week) or whole-grain bread (>5/week). A cumulative score ranging from 0 to 9 points was obtained. Patients were defined as low (0–2 pts), intermediate (3–5 pts), or high adherers to the Med-Diet (7–9 points) [37].
2.2. Serum TxB\(_2\) Assay

Serum Thromboxane (Tx) B\(_2\) was analyzed by an ELISA commercial kit (Cusabio, Houston, TX, USA), according to manufacturer instructions. The values were expressed as pg/mL. Intra- and inter-assay coefficients of variation for TxB\(_2\) were <8% and <10%, respectively.

2.3. Pro-C3 Assay

The detection of N-terminal propeptide of type III collagen (Pro-C3) was performed in serum samples by using Human PIIINP enzyme-linked immunosorbent assay (ELISA) (Novus Biological, Oceanside, CA, USA). Both intra- and inter-assay coefficients of variation for PIIINP were less than 10%.

2.4. Statistical Analysis

Categorical variables were reported as percentages; normal and non-normal continuous variables were reported as means ± SD and median and interquartile range [25–75th], respectively. Comparisons between groups were analyzed by ANOVA test and Bonferroni post hoc analysis or Kruskal–Wallis and Mann–Whitney tests (for continuous variables) or chi-square test (for categorical variables). Univariate analyses were conducted using Pearson correlation (r) analysis and Spearman correlation (rS) analysis for normal and non-normal variables, respectively.

Multivariate linear regression analyses were performed to test factors associated with TxB\(_2\) and Pro-C3. Non normal variables were log-transformed.

Multivariate logistic regression analyses were performed to test factors associated to TxB\(_2\) and Pro-C3. Lower tertiles were considered as reference ones.

A value of \( p < 0.05 \) was considered as statistically significant. All analyses were performed with SPSS V.27 and JMP software version 15-SAS Institute.

3. Results

3.1. Patients’ Characteristics According to Med-Diet Adherence

We included 655 NAFLD patients from the PLINIO study. Mean age was 54.9 ± 11.7 years and 38.6% were female. The median Med-Diet Score was 5 (4–6) points. According to score cut offs 10.2%, 74.3%, and 15.4% of the participants had low, intermediate, and high adherence to the Med-Diet, respectively. Patients with low adherence, as compared to those with high adherence, were younger, had higher prevalence of metabolic syndrome (70.1% vs. 52.5%, \( p = 0.022 \)), and higher median value of triglycerides (164.0 (114.0–212.0) mg/dl, \( p = 0.007 \)) and of GGT (30.5 (19.7–44.2) vs. 23.0 (17.0–33.2) UI/l, \( p = 0.028 \)) (Table 1). No differences were found in antiplatelet therapy according to the Med-Diet adherence group (Tables 1 and S1).

Table 1. Patients’ characteristics according to the adherence to Mediterranean Diet.

| Adherence to Mediterranean Diet | Low (Score 0–2 pts) \( (n = 67) \) | Intermediate (Score 3–6 pts) \( (n = 487) \) | High (Score 7–9 pts) \( (n = 101) \) | \( p \) among all | \( p \) low vs. high |
|---------------------------------|---------------------------------|---------------------------------|---------------------------------|-----------------|-----------------|
| Age (years)                     | 51.3 ± 13.1                     | 55.3 ± 11.4                     | 55.2 ± 11.6                     | 0.028           | 0.092           |
| Female (%)                      | 34.3                            | 40.7                            | 31.7                            | 0.181           | 0.721           |
| BMI (Kg/m\(^2\))                | 31.1 ± 5.4                      | 30.5 ± 5.0                      | 29.7 ± 4.3                      | 0.144           | 0.185           |
| Obesity (BMI ≥ 30 Kg/m\(^2\)) (%) | 53.7                            | 49.3                            | 41.6                            | 0.248           | 0.122           |
| Metabolic syndrome (%)          | 70.1                            | 61.1                            | 52.5                            | 0.063           | 0.022           |
| Waist circumference (cm)        | 108.2 ± 12.8                    | 107.2 ± 12.0                    | 105.8 ± 9.9                     | 0.392           | 0.581           |
| Diabetes (%)                    | 25.4                            | 29.2                            | 27.7                            | 0.797           | 0.736           |
Table 1. Cont.

| Adherence to Mediterranean Diet | Low (Score 0–2 pts) | Intermediate (Score 3–6 pts) | High (Score 7–9 pts) | P among all | P low vs. high |
|-------------------------------|---------------------|-------------------------------|----------------------|-------------|----------------|
| Glycaemia (mg/dL)             | 107.0 ± 38.4        | 106.1 ± 27.7                  | 102.9 ± 19.4         | 0.531       | 1.000          |
| Antiplatelet drugs (%)        | 20.9                | 15.6                          | 11.9                 | 0.288       | 0.114          |
| Statin use (%)                | 40.3                | 39.0                          | 33.7                 | 0.566       | 0.381          |
| Arterial hypertension (%)     | 56.7                | 61.4                          | 55.4                 | 0.456       | 0.871          |
| Total cholesterol (mg/dL)     | 202.1 ± 43.2        | 196.5 ± 42.1                  | 195.5 ± 38.7         | 0.554       | 0.950          |
| HDL (mg/dL)                   | 46.4 ± 10.7         | 47.9 ± 14.1                   | 47.5 ± 12.7          | 0.702       | 1.000          |
| Total cholesterol/HDL         | 4.6 ± 1.4           | 4.4 ± 1.7                     | 4.4 ± 1.3            | 0.690       | 1.000          |
| Triglycerides (mg/dL)         | 164.0 (114.0–212.0) | 137.0 (103.0–183.0)           | 127.0 (103.0–163.0)  | 0.026       | 0.007          |
| GGT (UI/L)                    | 30.5 (19.7–44.2)    | 28.0 (17.0–42.0)              | 23.0 (17.0–33.2)     | 0.074       | 0.028          |
| AST (UI/L)                    | 21.5 (18.0–28.2)    | 22.0 (18.0–29.0)              | 20.0 (17.0–26.7)     | 0.225       | 0.265          |
| ALT (UI/L)                    | 32.0 (20.0–43.0)    | 28.0 (20.0–44.0)              | 25.0 (18.0–35.0)     | 0.093       | 0.054          |
| Platelets                     | 250.9 ± 60.4        | 237.6 ± 63.0                  | 230.4 ± 52.3         | 0.109       | 0.108          |
| AST-to-Platelet ratio         | 0.3 (0.2–0.3)       | 0.3 (0.2–0.4)                 | 0.3 (0.2–0.3)        | 0.465       | 0.900          |
| TxB2 (pg/mL)                  | 191.4 ± 32.6        | 185.4 ± 33.2                  | 177.5 ± 24.1         | 0.015       | 0.017          |
| Pro-C3 (ng/mL)                | 7.8 ± 3.0           | 7.3 ± 2.7                     | 6.3 ± 1.7            | <0.001      | <0.001         |

BMI: body mass index; HDL: high-density lipoprotein; GGT: gamma-glutamyltransferase; AST: aspartate aminotransferase; ALT: alanine aminotransferase; TxB2: thromboxane B2; Pro-C3: N-terminal propeptide of type III collagen. Normal variables were expressed as mean ± SD; differences were tested using ANOVA test and Bonferroni post-hoc analysis; non-normal variables were expressed as median (25th–75th), differences were tested using Kruskal–Wallis and Mann–Whitney.

3.2. Med-Diet Score and TxB2

Mean TxB2 was 184.8 ± 32.0 pg/mL and decreased progressively from subjects with low Med-Diet adherence to those with intermediate and high adherence (191.4 ± 32.6 vs. 185.4 ± 33.2 vs. 177.5 ± 24.1 pg/mL, respectively, p = 0.015). No differences in mean TxB2 were found according to specific antiplatelet drugs (Table S2). At univariate analysis, the Med-Diet score correlated with TxB2 (rS = −0.100; p = 0.010). After correction for sex, total-c/HDL-c, glycaemia, BMI, and APRI, an independent negative association was demonstrated between serum TxB2 and the Med-Diet score (Beta = −0.10; p = 0.009), in addition to age (Beta = −0.09; p = 0.002) and APRI (Beta = 0.25; p < 0.001) (Table 2).

Table 2. Multivariate linear regression analysis of factors associated with TxB2.

| Panel A | B       | S.E. | Beta   | p     |
|---------|---------|------|--------|-------|
| Age     | −0.26   | 0.11 | −0.09  | 0.022 |
| Female sex | 2.73   | 2.64 | 0.04   | 0.300 |
| Total-c/HDL-c | 0.58 | 1.19 | 0.02   | 0.625 |
| Glycaemia | 0.02   | 0.05 | 0.02   | 0.661 |
| BMI     | −0.06   | 0.25 | −0.01  | 0.809 |
| Med-Diet score | −1.93 | 0.74 | −0.10  | 0.009 |
| Triglycerides * | −8.19 | 7.53 | −0.05  | 0.277 |
| APRI *  | 35.38   | 5.47 | 0.25   | <0.001|

Total-c: total cholesterol; HDL-c: high-density lipoprotein cholesterol; BMI: body mass index; TxB2: thromboxane B2; APRI: AST-to-platelets ratio; Pro-C3: N-terminal propeptide of type III collagen. * Non-normal variables were log-transformed.
At multivariate logistic regression analysis, high adherence to the Med-Diet (score > 6 pts) associated with TxB2 (III tertile vs. I tertile: OR = 0.55, p = 0.023 and II tertile vs. I tertile: OR = 0.56, p = 0.038) after correction for age > 65 years, sex, metabolic syndrome, and antiplatelet therapy. In addition, APRI > 0.7 associated with TxB2 (III tertile vs. I tertile: OR = 2.39, p = 0.039) (Table 3).

Table 3. Multivariate logistic regression analysis of factors associated TxB2 tertiles.

| Panel A | III TxB2 Tertile * | II TxB2 Tertile * |
|---------|-------------------|------------------|
|         | Odds Ratio (95% C.I for OR) | P | Odds Ratio (95% C.I for OR) | P |
| Age ≥ 65 years | 0.99 (0.62-1.57) | 0.956 | 0.50 (0.30-0.85) | 0.010 |
| Female Sex | 1.20 (0.81-1.78) | 0.364 | 1.42 (0.95-2.13) | 0.087 |
| Metabolic syndrome | 0.92 (0.62-1.36) | 0.682 | 1.34 (0.89-2.01) | 0.166 |
| Antiplatelet therapy | 0.91 (0.52-1.59) | 0.734 | 1.44 (0.84-2.47) | 0.182 |
| APRI > 0.7 | 2.39 (1.05-5.47) | 0.039 | 1.13 (0.43-3.06) | 0.813 |
| High adherence to Med-Diet | 0.55 (0.32-0.92) | 0.023 | 0.56 (0.33-0.97) | 0.038 |

C.I: confidence interval; OR: odds ratio; Total-c: total cholesterol; HDL-c: high-density lipoprotein cholesterol; BMI: body mass index; TxB2: thromboxane B2; APRI: AST-to-platelets ratio; Pro-C3: N-terminal propeptide of type III collagen. * I TxB2 tertile was considered as reference.

Performing additional multivariate analyses using each food score items instead of the Med-Diet adherence score, TxB2 (II vs. I tertile: OR = 0.45, p < 0.001, III vs. I tertile: OR = 0.57, p = 0.004) correlated with low meat consumption (meat < 1 serving/day) after correction for age > 65 years, sex, metabolic syndrome, antiplatelet therapy and APRI > 0.7 (Figure 1).

Figure 1. Multivariate regression analyses of factors associating with each Mediterranean diet food score items. (TxB2 odds ratio and relative confidence interval were adjusted for age > 65 years, sex, metabolic syndrome, antiplatelet therapy, APRI > 0.7). * p < 0.001; ° p = 0.004.

3.3. Med-Diet Score and Pro-C3

In the whole population the mean Pro-C3 was 7.2 ± 2.6 ng/mL and decreased progressively from subjects with low Med-Diet adherence to those with intermediate and high adherence (7.8 ± 3.0 vs. 7.3 ± 2.7 vs. 6.3 ± 1.7 ng/mL, respectively, p < 0.001). No differences in mean Pro-C3 were found according to specific antiplatelet drugs (Table S2).
At univariate analysis, a negative correlation was observed between the Med-Diet score and Pro-C3 ($r = -0.135; p < 0.001$). After correction for age, sex, total-c/HDL-c, glycaemia, and BMI, Pro-C3 associated with the Med-Diet score ($\beta = -0.12; p = 0.002$) and APRI ($\beta = 0.10, p = 0.008$) (Table 4).

**Table 4. Multivariate linear regression analyses of factors associated with Pro-C3.**

|            | B       | S.E. | Beta | p       |
|------------|---------|------|------|---------|
| Age        | -0.01   | 0.01 | -0.05 | 0.273   |
| Female sex | 0.12    | 0.22 | 0.02  | 0.593   |
| Total-c/HDL-c | -0.15  | 0.10 | -0.08 | 0.133   |
| Glycaemia  | 0.00    | 0.00 | 0.03  | 0.469   |
| BMI        | 0.03    | 0.02 | 0.05  | 0.214   |
| Med-Diet score | -0.19 | 0.06 | -0.12 | 0.002   |
| Triglycerides * | -0.14 | 0.64 | -0.01 | 0.821   |
| APRI *     | 1.22    | 0.46 | 0.10  | 0.008   |

Total-c: total cholesterol; HDL-c: high-density lipoprotein cholesterol; BMI: body mass index; TxB$_2$: thromboxane B$_2$; APRI: AST-to-platelets ratio; Pro-C3: N-terminal propeptide of type III collagen. * Non-normal variables were log-transformed.

At multivariate logistic regression analysis, high adherence to the Med-Diet (score > 6 pts) was associated with Pro-C3 (III vs. I tertile: OR = 0.48, $p = 0.010$) after correction for sex, metabolic syndrome, and antiplatelet therapy. In addition, age $\geq$ 65 years associated with Pro-C3 tertiles (III vs. I tertile: OR = 0.60, $p = 0.038$; II vs. I tertile: OR = 0.57, $p = 0.023$) (Table 5).

**Table 5. Multivariate logistic regression analyses of factors associated with Pro-C3 tertiles.**

|            | III Pro-C3 Tertile * | Odds Ratio (95% C.I for OR) | $p$     | II Pro-C3 Tertile * | Odds Ratio (95% C.I for OR) | $p$     |
|------------|----------------------|-----------------------------|---------|----------------------|-----------------------------|---------|
| Age $\geq$ 65 years | 0.60 (0.37–0.97) | 0.038 | 0.57 (0.35–0.92) | 0.023 |
| Female Sex | 1.23 (0.82–1.84) | 0.307 | 1.44 (0.97–2.15) | 0.073 |
| Metabolic Syndrome | 1.00 (0.67–1.50) | 0.993 | 0.89 (0.59–1.34) | 0.579 |
| Antiplatelet therapy | 0.99 (0.58–1.69) | 0.982 | 0.73 (0.42–1.27) | 0.271 |
| APRI > 0.7 | 1.66 (0.75–3.65) | 0.208 | 0.62 (0.23–1.65) | 0.336 |
| High Adherence to Med-Diet | 0.48 (0.27–0.84) | 0.010 | 0.89 (0.54–1.48) | 0.563 |

C.I: confidence interval; OR: odds ratio; Total-c: total cholesterol; HDL-c: high-density lipoprotein cholesterol; BMI: body mass index; TxB$_2$: thromboxane B$_2$; APRI: AST-to-platelets ratio; Pro-C3: N-terminal propeptide of type III collagen. * I Pro-C3 tertile was considered as reference.

When in the multivariate analyses, the individual food items scores were included as independent variables instead of the Med-Diet score, no statistically significant associations with Pro-C3 tertiles were observed (data not showed).

At univariate analysis, TxB$_2$ and Pro-C3 were positively correlated ($r = 0.110; p = 0.005$). The correlation was also confirmed after adjustment for age and sex ($\beta = 0.106; p = 0.007$).

### 4. Discussion

The beneficial effects of the Med-Diet were widely proved. Previous studies have demonstrated anti-inflammatory [38] and antioxidant effects in both the general population [39] and NAFLD patients [24]. Instead, this is the first study proving an inverse correlation between Med-Diet adherence, circulating platelet activation marker, and liver collagen deposition in patients with NAFLD.
Platelet activation is a key moment in atherothrombotic processes leading to CVD. CVD is the first cause of morbidity and mortality in patients with NAFLD [40,41]. While impaired lipid profile [42], diabetes [43], endothelial dysfunction [44], and oxidative stress [45,46] were investigated as possible risk factors in NAFLD patients, few studies have addressed platelet activation as a cardiovascular risk marker. Some authors have suggested mean platelet volume (MPV), a reliable marker of platelet hyperactivity and CV risk [47], as a risk marker in NAFLD patients, and have included MPV in a risk score for CV events in these patients [43].

To the best of our knowledge, this is the first study reporting TxB2 levels in a large population of NAFLD patients and investigating the relationship between TxB2 and adherence to the Med-Diet in this setting. Serum TxB2, produced by the non-enzymatic hydration of thromboxane A2, which is produced in turn by platelet cyclooxygenase 1 [48], reflects the body production of TxB2 and is a reliable marker of platelet activation ex vivo [49]. Whereas in other settings, such as atrial fibrillation [50] and pneumonia [51], the relationship between platelet activation, the Med-Diet, and cardiovascular events is well described, to date, there are no prospective data on the association between Med-Diet adherence, TxB2, and cardiovascular events in NAFLD patients.

Our data also demonstrate for the first time that the lower the adherence to the Med-Diet, the higher the values of serum Pro-C3, confirming that the Med-Diet might be associated with a less severe NAFLD. Serum Pro-C3, cleaved during collagen III deposition, is a circulating marker of fibrogenesis that progressively increase with fibrosis stage and NAFLD activity score (NAS) [19]. Of interest, we found a direct correlation between Pro-C3 and APRI, a noninvasive score of liver fibrosis. In accordance with our data, a previous study form Kontogianni MD et al. showed an inverse correlation between Med-Diet adherence and both liver fibrosis (diagnosed with histology or liver stiffness measurement) and NASH diagnosis [52].

When we analyzed the single food items of the Med-Diet score, we found that none of them associated with higher values of Pro-C3, suggesting a role of the Med-Diet as a whole in influencing collagen liver deposition.

Instead, performing a further analysis including TxB2, we found that lower consumption of meat (less than 1 serving/week) associates with lower levels of serum TxB2, suggesting a less severe NAFLD in patients who eat less meat. Differently, Pignatelli et al. [29] demonstrated that, in atrial fibrillation patients, high olive oil consumption inversely correlated with the level of TxA2 production.

Our data could partially be explained by previous findings. Ahmad M.I. and colleagues [53], linked diets rich in red meat and NAFLD risk via the high oxidative stress induced by this dietary pattern. Interestingly, we previously demonstrated, although in different settings, the association between low adherence to the Mediterranean diet and both high circulating level of lipopolysaccharide (LPS) and NADPH oxidase 2 (NOX2), markers of gut bacterial products translocation and systemic oxidative stress, respectively [24,54]. Oxidative stress is a well-known factor inducing platelet activation [55] and could represent the link between meat consumption and impaired platelet activation.

In addition, we found an independent association between TxB2 and Pro-C3 that might confirm a role of platelet activity in liver damage as also supported by the association between TxB2 and APRI.

Finally, this study confirms, as previously observed [23], that older patients adhere more to the Med-Diet than younger ones. This finding is in agreement with that observed in other Italian study populations [56]. The trend of Mediterranean youth to prefer Western dietary habits was widely discussed in the literature in the last years [57,58] and was summarized in a systematic review [59]. This has been related to the more frequent habits to have lunch away from home because of work [57]. Interestingly, in the last 2 years, during COVID19 pandemic, young adults [18–30 years] paid more attention to eating Med-Diet foods [60].
Our findings have clinical implication, adding evidence on the beneficial role of the Med-Diet in preventing both NAFLD progression and cardiovascular disease in this setting. Previous studies already proved that high adherence to the Med-Diet induces effective weight loss, liver fat, and total mass fat reduction, liver stiffness, and ALT improvement [61–63]. Of note, the Med-Diet score we used was validated in a study aimed to the quantitative estimation of adherence to a cardioprotective Mediterranean diet [37], giving even more strength to the association between Med-Diet adherence and TxB2 we found.

Our study has also some limitations. Its observational and cross-sectional design does not allow the establishment of a cause–effect relationship between Med-Diet adherence, impaired platelet activity, and liver collagen deposition. In addition, the Med-Diet short questionnaire we used was not designed to investigate single nutrient intake and we therefore could not investigate the association between serum TxB2 and Pro-C3 with specific nutrients. Finally, despite US scanning being the most suitable imaging test to diagnose liver steatosis, due its cost-effectiveness and high specificity, it has a low diagnostic sensitivity for mild steatosis.

5. Conclusions

NAFLD patients high adhering to the Med-Diet show lower platelet activation and liver collagen III deposition, suggesting a protective role of the Med-Diet against NAFLD progression and cardiovascular risk. In addition, the positive correlation between serum TxB2 and Pro-C3 may suggest a link between NAFLD severity and the level of cardiovascular risk.

Supplementary Materials: The following supporting information can be downloaded at: https://www.mdpi.com/article/10.3390/nu14061209/s1; Table S1: Multivariate linear regression analysis of factor associated with Mediterranean Diet Score, including both TxB2 and Pro-C3; Table S2: Multivariate logistic regression analysis of factors associated with high adherence to Mediterranean Diet (score > 6 pts), including both TxB2 and Pro-C3 tertiles.

Author Contributions: Conceptualization, F.B., V.C. (Vittoria Cammisotto) and M.D.B.; methodology, F.B., V.C. (Vittoria Cammisotto), P.P., R.C. and M.D.B.; formal analysis, F.B., F.A. and V.C. (Vittoria Cammisotto); investigation, G.T., S.B., M.C., C.N., V.C. (Valentina Castellani) and A.D.; data curation, G.T., S.B., M.C. and C.N. and A.D.; writing—original draft preparation, F.B., V.C. (Vittoria Cammisotto) and M.D.B.; writing—review and editing, F.B., V.C. (Vittoria Cammisotto), P.P., R.C., G.T., S.B., M.C., V.C. (Valentina Castellani) C.N., A.D., F.A. and M.D.B.; supervision, M.D.B.; project administration, F.B. and M.D.B. All authors have read and agreed to the published version of the manuscript.

Funding: This research received no external funding, APC was founded by Sapienza – University of Rome.

Institutional Review Board Statement: The study was conducted according to the 2008 update of the Declaration of Helsinki. All patients subscribed informed written consent. Study protocol was approved by the local ethical board of Sapienza-University of Rome (Ref. 2277 prot. 873/11). All co-authors had access to the study data and had reviewed and approved the final manuscript.

Informed Consent Statement: Informed consent was obtained from all subjects involved in the study.

Data Availability Statement: The data presented in this study are available on request from the corresponding author.

Conflicts of Interest: The authors declare no conflict of interest.

References
1. UNESCO. Representative List of the Intangible Culture Heritage of Humanity. Available online: https://ich.unesco.org/en/RL/mediterranean-diet-00884 (accessed on 22 January 2022).
2. Gussow, J.D. Mediterranean diets: Are they environmentally responsible? Am. J. Clin. Nutr. 1995, 61, 1383S–1389S. [CrossRef] [PubMed]
3. Pairotti, M.B.; Cerutti, A.K.; Martini, F.; Vescos, E.; Padovan, D.; Beltramo, R. Energy consumption and GHG emission of the Mediterranean diet: A systemic assessment using a hybrid LCA-IO method. *J. Clin. Prod.* 2015, 103, 507–516. [CrossRef]

4. Boucher, J.L. Mediterranean Eating Pattern. *Diabetes Spectr.* 2017, 30, 72–76. [CrossRef] [PubMed]

5. Keys, A.; Aravanis, C.; Blackburn, H.W.; Van Buchem, F.S.; Buzina, R.; Djordjević, B.D.; Dontas, A.S.; Fidanza, F.; Karvonen, M.J.; Kimura, N.; et al. Epidemiological studies related to coronary heart disease: Characteristics of men aged 40–79 in seven countries. *Acta Med. Scand. Suppl.* 1966, 460, 1–392. [CrossRef] [PubMed]

6. Estruch, R.; Ros, E.; Salas-Salvadó, J.; Covas, M.I.; Corella, D.; Arós, F.; Gómez-Gracia, E.; Ruiz-Gutiérrez, V.; Fiol, M.; Lapetra, J.; et al. Primary Prevention of Cardiovascular Disease with a Mediterranean Diet Supplemented with Extra-Virgin Olive Oil or Nuts. *N. Engl. J. Med.* 2018, 378, e34. [CrossRef] [PubMed]

7. Trichopoulou, A.; Costacou, T.; Bamia, C.; Trichopoulou, D. Adherence to a Mediterranean diet and survival in a Greek population. *N. Engl. J. Med.* 2003, 348, 2599–2608. [CrossRef] [PubMed]

8. Shai, I.; Schwarzfuchs, D.; Henkin, Y.; Shahar, D.R.; Witkop, S.; Greenberg, I.; Golan, R.; Fraser, D.; Bolotin, A.; Vardi, H.; et al. Weight loss with a low-carbohydrate, Mediterranean, or low-fat diet. *N. Engl. J. Med.* 2008, 359, 229–241. [CrossRef] [PubMed]

9. Schwingshackl, L.; Morze, J.; Hoffmann, G. Mediterranean diet and health status: Active ingredients and pharmacological mechanisms. *Br. J. Pharm.* 2020, 177, 1241–1257. [CrossRef] [PubMed]

10. Esposito, K.; Marfella, R.; Ciotti, M.; Di Palo, C.; Giugliano, F.; Giugliano, G.; D’Armiento, M.; D’Andrea, F.; Giugliano, D. Effect of a Mediterranean-style diet on endothelial function and markers of vascular inflammation in the metabolic syndrome: A randomized trial. *JAMA* 2004, 292, 1440–1446. [CrossRef] [PubMed]

11. Davis, C.R.; Hodgson, J.M.; Woodman, R.; Bryan, J.; Wilson, C.; Murphy, K.J. A Mediterranean diet lowers blood pressure and improves endothelial function: Results from the MedLey randomized intervention trial. *Am. J. Clin. Nutr.* 2017, 105, 1305–1313. [CrossRef]

12. Younossi, Z.; Anstee, Q.M.; Marietti, M.; Hardy, T.; Henry, L.; Eslam, M.; George, J.; Bugianesi, E. Global burden of NAFLD and NASH: Trends, predictions, risk factors and prevention. *Nat. Rev. Gastroenterol. Hepatol.* 2018, 15, 11–20. [CrossRef] [PubMed]

13. Anstee, Q.M.; Reeves, H.L.; Kotsiliti, E.; Govaere, O.; Heikenwalder, M. From NASH to HCC: Current concepts and future challenges. *Nat. Rev. Gastroenterol. Hepatol.* 2019, 16, 411–428. [CrossRef] [PubMed]

14. Younossi, Z.M.; Koenig, A.B.; Abdelatif, D.; Fazel, Y.; Henry, L.; Wymer, M. Global epidemiology of nonalcoholic fatty liver disease-Meta-analytic assessment of prevalence, incidence, and outcomes. *Hepatology* 2016, 64, 73–84. [CrossRef] [PubMed]

15. Del Ben, M.; Polimeni, L.; Brancorsini, M.; Di Costanzo, A.; D’Erasmo, L.; Baratta, F.; Loffredo, L.; Pastori, D.; Pignatelli, P.; Violi, F.; et al. Non-alcoholic fatty liver disease, metabolic syndrome and patatin-like phospholipase domain-containing protein3 gene variants. *Eur. J. Intern. Med.* 2014, 25, 566–570. [CrossRef] [PubMed]

16. EASL-EASD-EASO. Clinical Practice Guidelines for the management of non-alcoholic fatty liver disease. *J. Hepatol.* 2016, 64, 1388–1402. [CrossRef] [PubMed]

17. Ryan, M.C.; Issiopoulos, C.; Thodis, T.; Ward, G.; Trost, N.; Hofferberth, S.; O’Dea, K.; Desmond, P.; Johnson, N.A.; Wilson, A.M. The Mediterranean diet improves hepatic steatosis and insulin sensitivity in individuals with non-alcoholic fatty liver disease. *J. Hepatol.* 2013, 59, 138–143. [CrossRef] [PubMed]

18. Kouvari, M.; Boutari, C.; Chrysohoou, C.; Fragiopoulos, E.; Antonopoulou, S.; Tousoulis, D.; Pitsavos, C.; Panagiotakos, D.B.; Mantzoros, C.S.; Investigators, A.S. Mediterranean diet is inversely associated with steatosis and fibrosis and decreases ten-year diabetes and cardiovascular risk in NAFLD subjects: Results from the ATTICA prospective cohort study. *Clin. Nutr.* 2021, 40, 3314–3324. [CrossRef] [PubMed]

19. Boyle, M.; Tiniakos, D.; Schattenberg, J.M.; Ratziu, V.; Fiol, M.; Lapetra, J.; et al. Performance of the PRO-C3 collagen neo-epitope biomarker in non-alcoholic fatty liver disease. *JHEP Rep.* 2019, 1, 188–198. [CrossRef] [PubMed]

20. Nielsen, M.J.; Nedergaard, A.F.; Sun, S.; Veidal, S.S.; Larsen, L.; Zheng, Q.; Suetta, C.; Henrikssen, K.; Christiansen, C.; Karsdal, M.A.; et al. The neo-epitope specific PRO-C3 ELISA measures true formation of type III collagen associated with liver and muscle parameters. *Am. J. Transl. Res.* 2015, 7, 303–315. [CrossRef] [PubMed]

21. Gressner, A.M.; Weiskirchen, R. Modern pathogenetic concepts of liver fibrosis suggest stellate cells and TGF-beta as major players and therapeutic targets. *J. Cell. Mol. Med.* 2006, 10, 76–99. [CrossRef]

22. Frei, A.; Zimmermann, A.; Weigand, K. The N-terminal propeptide of collagen type III in serum reflects activity and degree of fibrosis in patients with chronic liver disease. *Hepatology* 1984, 4, 830–834. [CrossRef]

23. Baratta, F.; Pastori, D.; Polimeni, L.; Bucci, T.; Ceci, F.; Calabrese, C.; Ernesti, I.; Parrinetti, G.; Violi, F.; Angelico, F.; et al. Adherence to Mediterranean Diet and Non-Alcoholic Fatty Liver Disease: Effect on Insulin Resistance. *Am. J. Gastroenterol.* 2017, 112, 1832–1839. [CrossRef]

24. Baratta, F.; Pastori, D.; Bartimoccia, S.; Cammisotto, V.; Cocomotto, N.; Colantonio, A.; Nozella, C.; Carnevale, R.; Ferro, D.; Angelico, F.; et al. Poor Adherence to Mediterranean Diet and Serum Lipopolysaccharide are Associated with Oxidative Stress in Patients with Non-Alcoholic Fatty Liver Disease. *Nutrients* 2020, 12, 1732. [CrossRef] [PubMed]

25. Kawaguchi, T.; Charlton, M.; Kawaguchi, A.; Yamamura, S.; Nakano, D.; Tsutsumi, T.; Zafer, M.; Torimura, T. Effects of Mediterranean Diet in Patients with Nonalcoholic Fatty Liver Disease: A Systematic Review, Meta-Analysis, and Meta-Regression Analysis of Randomized Controlled Trials. *Semin. Liver Dis.* 2021, 41, 225–234. [CrossRef] [PubMed]
26. Carpino, G.; Del Ben, M.; Pastori, D.; Carnevale, R.; Baratta, F.; Overi, D.; Francis, H.; Cardinale, V.; Onorini, P.; Safarikia, S.; et al. Increased liver localization of lipopolysaccharides in human and experimental non-alcoholic fatty liver disease. *Hepatology* 2019, 72, 470–485. [CrossRef]

27. Malehm, M.; Pfister, D.; Gallage, S.; Szydłowska, M.; Inverso, D.; Kotsili, E.; Leone, V.; Peiseler, M.; Surewaard, B.G.J.; Rath, D.; et al. Platelet GP1ba is a mediator and potential interventional target for NASH and subsequent liver cancer. *Nat. Med.* 2019, 25, 641–655. [CrossRef]

28. Hernández, A.; Castañer, O.; Tresserra-Rimbau, A.; Pintó, X.; Fitó, M.; Casas, R.; Martínez-González, M.; Corella, D.; Salas-Salvadó, J.; Lapetra, J.; et al. Mediterranean Diet and Atherothrombosis Biomarkers: A Randomized Controlled Trial. *Mol. Nutr. Food Res.* 2020, 64, 2000350. [CrossRef]

29. Pigugliati, P.; Pastori, D.; Farcomeni, A.; Nocella, C.; Bartimoccia, S.; Vicario, T.; Bucci, T.; Carnevale, R.; Violi, F. Mediterranean diet reduces thromboxone A2 production in atrial fibrillation patients. *Clin. Nutr.* 2015, 34, 899–903. [CrossRef] [PubMed]

30. Bush, K.; Kivlahan, D.R.; McDonell, M.B.; Fihn, S.D.; Bradley, K.A. The AUDIT alcohol consumption questions (AUDIT-C): An effective brief screening test for problem drinking. Ambulatory Care Quality Improvement Project (ACQUIP). Alcohol Use Disorders Identification Test. *Arch. Intern. Med.* 1999, 158, 1789–1795. [CrossRef] [PubMed]

31. Grundy, S.M.; Cleeman, J.I.; Daniels, S.R.; Donato, K.A.; Eckel, R.H.; Franklin, B.A.; Gordon, D.J.; Krauss, R.M.; Savage, P.J.; Smith, S.C., Jr.; et al. Diagnosis and management of the metabolic syndrome: An American Heart Association/National Heart, Lung, and Blood Institute Scientific Statement. *Circulation* 2005, 112, 2735–2752. [CrossRef]

32. Williams, B.; Mancia, G.; Spiering, W.; Agabiti Rosei, E.; Burnier, M.; Clement, D.; Coca, A.; De Simone, G.; Dominiczak, A.; et al. Practice Guidelines for the management of arterial hypertension of the European Society of Hypertension and the European Society of Cardiology: ESH/ESC Task Force for the Management of Arterial Hypertension. *J. Hypertens.* 2018, 36, 2284–2309. [CrossRef] [PubMed]

33. American Diabetes Association. 2. Classification and Diagnosis of Diabetes. *Diabetes Care* 2020, 43, S14–S31. [CrossRef]

34. Hamaguchi, M.; Kojima, T.; Itoh, Y.; Harano, Y.; Fujii, K.; Nakajima, T.; Kato, T.; Takeda, N.; Okuda, J.; Ida, K.; et al. The severity of ultrasonographic findings in nonalcoholic fatty liver disease reflects the metabolic syndrome and visceral fat accumulation. *Am. J. Gastroenterol.* 2007, 102, 2708–2715. [CrossRef] [PubMed]

35. Williams, B.; Mancia, G.; Spiering, W.; Agabiti Rosei, E.; Azizi, M.; Burnier, M.; Clement, D.; Coca, A.; De Simone, G.; Dominiczak, A.; et al. Practice Guidelines for the management of arterial hypertension of the European Society of Hypertension and the European Society of Cardiology: ESH/ESC Task Force for the Management of Arterial Hypertension. *J. Hypertens.* 2018, 36, 2284–2309. [CrossRef] [PubMed]

36. Martínez-González, M.A.; Fernández-Jarne, E.; Serrano-Martínez, M.; Wright, M.; Gomez-Gracia, E. Development of a short dietary intake questionnaire for the quantitative estimation of adherence to a cardioprotective Mediterranean diet. *Eur. J. Clin. Nutr.* 2004, 58, 1550–1552. [CrossRef] [PubMed]

37. Sureda, A.; Bibiloni, M.D.M.; Julibert, A.; Bouzas, C.; Argelich, E.; Llompart, I.; Pons, A.; Tur, J.A. Adherence to the Mediterranean Diet and Inflammatory Markers. *Nutrients* 2018, 10, 62. [CrossRef] [PubMed]

38. Sureda, A.; Bibiloni, M.D.; Martorell, M.; Buil-Cosiales, P.; Martí, A.; Pons, A.; Tur, J.A.; Martínez-González, M.; Investigators, P.S. Mediterranean diets supplemented with virgin olive oil and nuts enhance plasmatic antioxidant capabilities and decrease xanthine oxidase activity in people with metabolic syndrome: The PREDIMED study. *Mol. Nutr. Food Res.* 2016, 60, 2654–2664. [CrossRef] [PubMed]

39. Rinella, M.E. Nonalcoholic fatty liver disease: A systematic review. *JAMA* 2015, 313, 2263–2273. [CrossRef]

40. Angulo, P.; Kleiner, D.E.; Hanley, L.A.; Bismuth, E.; Magnanimi, E.; Staley, P.; Mills, P.R.; Peach, J.C.; Lafferty, S.H.; et al. Liver Fibrosis, but No Other Histologic Features, Is Associated with Long-term Outcomes of Patients with Non-Alcoholic Fatty Liver Disease. *Gastroenterology* 2015, 149, 389–397. [CrossRef]

41. Pastori, D.; Baratta, F.; Del Ben, M. Remnant Lipoprotein Cholesterol and Cardiovascular and Cerebrovascular Events in Patients with Non-Alcoholic Fatty Liver Disease. *J. Clin. Med.* 2018, 7, 378. [CrossRef]

42. Acebes, R.D.; Bullinsky, B.H.; Forlano, R.; Kimhofer, T.; Adler, M.; Tzallas, A.; Giannakeas, N.; Yee, M.; Mayet, J.; Goldin, R.D.; et al. Derivation and validation of a cardiovascular risk score for prediction of major acute cardiovascular events in non-alcoholic fatty liver disease; the importance of an elevated mean platelet volume. *Am. J. Cardiol.* 2015, 115, 1402–1406. [CrossRef] [PubMed]

43. Pastori, D.; Loffredo, L.; Parì, A.; Francorcesi, M.; Albanese, F.; Catasus, E.; et al. Relation of nonalcoholic fatty liver disease and Framingham Risk Score to flow-mediated dilation in patients with cardiometabolic risk factors. *Am. J. Cardiol.* 2015, 115, 1402–1406. [CrossRef] [PubMed]

44. Ma, Y.; Lee, G.; Heo, S.Y.; Roh, Y.S. Oxidative Stress Is a Key Modulator in the Development of Nonalcoholic Fatty Liver Disease. *Antioxidants* 2021, 11, 91. [CrossRef] [PubMed]

45. Ferro, D.; Baratta, F.; Pastori, D.; Cocomello, N.; Colontoni, A.; Angelico, F.; Del Ben, M. New Insights into the Pathogenesis of Non-Alcoholic Fatty Liver Disease: Gut-Derived Lipopolysaccharides and Oxidative Stress. *Nutrients* 2020, 12, 2762. [CrossRef]

46. Renga, B.; Scavizzi, F. Platelets and cardiovascular risk. *Acta Cardiol.* 2017, 72, 2–8. [CrossRef]
48. FitzGerald, G.A. Mechanisms of platelet activation: Thromboxane A2 as an amplifying signal for other agonists. *Am. J. Cardiol.* 1991, 68, 11B–15B. [CrossRef]

49. Catella, F.; Healy, D.; Lawson, J.A.; FitzGerald, G.A. 11-Dehydrothromboxane B2: A quantitative index of thromboxane A2 formation in the human circulation. *Proc. Natl. Acad. Sci. USA* 1986, 83, 5861–5865. [CrossRef] [PubMed]

50. Pastori, D.; Pignatelli, P.; Farcomeni, A.; Nocella, C.; Bartimoccia, S.; Carnevale, R.; Violi, F. Age-related increase of thromboxane B2 and risk of cardiovascular disease in atrial fibrillation. *Oncotarget* 2016, 7, 39143–39147. [CrossRef] [PubMed]

51. Cangemi, R.; Cacciari, M.; Rossi, E.; Calvieri, C.; Bucci, T.; Calabrese, C.M.; Taliani, G.; Falcone, M.; Falange, P.; Bertazzoni, G.; et al. Platelet activation is associated with myocardial infarction in patients with pneumonia. *J. Am. Coll. Cardiol.* 2014, 64, 1917–1925. [CrossRef]

52. Kontogianni, M.D.; Tileli, N.; Margariti, A.; Georgoulis, M.; Deutsch, M.; Tiniakos, D.; Fragopoulou, E.; Zafiropoulou, R.; Manios, Y.; Papatheodoridis, G. Adherence to the Mediterranean diet is associated with the severity of non-alcoholic fatty liver disease. *Clin. Nutr.* 2014, 33, 678–683. [CrossRef]

53. Ahmad, M.I.; Umair Ijaz, M.; Hussain, M.; Ali Khan, I.; Mehmood, N.; Siddiqi, S.M.; Liu, C.; Zhao, D.; Xu, X.; Zhou, G.; et al. High fat diet incorporated with meat proteins changes biomarkers of lipid metabolism, antioxidant activities, and the serum metabolomic profile in Glrx1. *Food Funct.* 2020, 11, 236–252. [CrossRef]

54. Carnevale, R.; Pastori, D.; Nocella, C.; Cammisotto, V.; Bartimoccia, S.; Novo, M.; Del Ben, M.; Farcomeni, A.; Angelico, F.; Violi, F. Gut-derived lipopolysaccharides increase post-prandial oxidative stress via Nox2 activation in patients with impaired fasting glucose tolerance: Effect of extra-virgin olive oil. *Eur. J. Nutr.* 2019, 58, 843–851. [CrossRef]

55. Violi, F.; Loffredo, L.; Carnevale, R.; Pignatelli, P.; Pastori, D. Atherothrombosis and Oxidative Stress: Mechanisms and Management in Elderly. *Antioxid. Redox Signal.* 2017, 27, 1083–1124. [CrossRef] [PubMed]

56. Pelucchi, C.; Galeone, C.; Negri, E.; La Vecchia, C. Trends in adherence to the Mediterranean diet in an Italian population between 1991 and 2006. *Eur. J. Clin. Nutr.* 2010, 64, 1052–1056. [CrossRef] [PubMed]

57. Allman-Farinelli, M.; Partridge, S.R.; Roy, R. Weight-Related Dietary Behaviors in Young Adults. *Curr. Obes. Rep.* 2016, 5, 23–29. [CrossRef]

58. Šarac, J.; Havaš Auguštin, D.; Lovrić, M.; Stryeck, S.; Šunić, I.; Novokmet, N.; Missoni, S. A Generation Shift in Mediterranean Diet Adherence and Its Association with Biological Markers and Health in Dalmatia, Croatia. *Nutrients* 2021, 13, 4564. [CrossRef]

59. García Cabrera, S.; Herrera Fernández, N.; Rodríguez Hernández, C.; Nissensohn, M.; Román-Viñas, B.; Serra-Majem, L. KIDMED test; Prevalence of low adherence to the Mediterranean diet in children and young.; A systematic review. *Nutr. Hosp.* 2015, 32, 2390–2399. [CrossRef]

60. Di Renzo, L.; Gualtieri, P.; Pivari, F.; Soldati, L.; Attinà, A.; Cinelli, G.; Leggeri, C.; Caparello, G.; Barrea, L.; Scerbo, F.; et al. Eating habits and lifestyle changes during COVID-19 lockdown: An Italian survey. *J. Transl. Med.* 2020, 18, 129. [CrossRef]

61. Yaskolka Meir, A.; Rinott, E.; Tsaban, G.; Zelicha, H.; Kaplan, A.; Shelef, I.; Youngster, I.; Shalev, A.; Blüher, M.; et al. Effect of green-Mediterranean diet on intrahepatic fat: The DIRECT PLUS randomised controlled trial. *Gut* 2021, 70, 2085–2095. [CrossRef]

62. Marin-Alejandre, B.A.; Abete, I.; Cantero, I.; Monreal, J.I.; Elorz, M.; Herrero, J.I.; Martínez-Echeverría, A.; Uriz-Otano, J.I.; et al. The Metabolic and Hepatic Impact of Two Personalized Dietary Strategies in Subjects with Obesity and Nonalcoholic Fatty Liver Disease: The Fatty Liver in Obesity (FLiO) Randomized Controlled Trial. *Nutrients* 2019, 11, 2543. [CrossRef]

63. Katsagoni, C.N.; Papatheodoridis, G.V.; Ioannidou, P.; Deutsch, M.; Alexopoulou, A.; Papadopoulos, N.; Papageorgiou, M.V.; Fragopoulou, E.; Kontogianni, M.D. Improvements in clinical characteristics of patients with non-alcoholic fatty liver disease, after an intervention based on the Mediterranean lifestyle: A randomised controlled clinical trial. *Br. J. Nutr.* 2018, 120, 164–175. [CrossRef] [PubMed]